Search

Your search keyword '"Deborah Barbouth"' showing total 63 results

Search Constraints

Start Over You searched for: Author "Deborah Barbouth" Remove constraint Author: "Deborah Barbouth"
63 results on '"Deborah Barbouth"'

Search Results

7. Genome sequencing reveals novel noncoding variants in PLA2G6 and LMNB1 causing progressive neurologic disease

8. Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort

9. Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11

10. Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

11. A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder

12. Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases

13. Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science

14. A concurrent dual analysis of genomic data augments diagnoses: Experiences of 2 clinical sites in the Undiagnosed Diseases Network

15. One is the loneliest number: genotypic matchmaking using the electronic health record

16. Genome sequencing reveals novel noncoding variants in <scp> PLA2G6 </scp> and <scp> LMNB1 </scp> causing progressive neurologic disease

17. A founder noncoding<scp>GALT</scp>variant interfering with splicing causes galactosemia

18. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder

19. Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7

20. De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation

21. Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy

22. Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification

23. Early-Onset Marfan Syndrome: A Case Series

24. An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

25. COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic

26. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

27. COVID‐19 in a child with severe propionic acidemia

28. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges

29. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling

30. Infantile Onset Hypertrophic Cardiomyopathy Secondary to PRKAG2 Gene Mutation is Associated with Poor Prognosis

31. Dual Molecular Effects of Dominant RORA Mutations Cause Two Variants of Syndromic Intellectual Disability with Either Autism or Cerebellar Ataxia

32. MPV17-related mitochondrial DNA maintenance defect: New cases and review of clinical, biochemical, and molecular aspects

33. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

34. Correction: Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

35. De Novo Pathogenic Variants in N-cadherin Cause a Syndromic Neurodevelopmental Disorder with Corpus Callosum, Axon, Cardiac, Ocular, and Genital Defects

36. De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas, Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia

37. Arnold-Chiari type 1 malformation in Potocki-Lupski syndrome

38. Uniparental Disomy Causing Myoclonus Dystonia Associated with Russell Silver Syndrome

39. Klinefelter Syndrome in Association with Tetralogy of Fallot and Congenital Diaphragmatic Hernia

40. Fragile X Syndrome: A Review of Associated Medical Problems

41. De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder

42. Knowledge, attitudes, and barriers to carrier screening for the Ashkenazi Jewish panel: a Florida experience

43. Genotype-phenotype analysis of 4q deletion syndrome: Proposal of a critical region

44. Expanded newborn screening in Puerto Rico and the US Virgin Islands: education and barriers assessment

45. Prevention of a molecular misdiagnosis in galactosemia

46. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: Analysis of eight sibling pairs

47. Correlation between birth weight, disease severity and outcomes in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS)

48. Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome

49. Patient management problem-preferred responses

50. Screening newborns for galactosemia using total body galactose oxidation to CO2 in expired air

Catalog

Books, media, physical & digital resources